AGIOS PHARMACEUTICALS, INC. 4

Jay T. Backstrom acquired 1,447 shares of Agios Pharmaceuticals, Inc. common stock upon vesting/conversion of restricted stock units, bringing his direct holdings to 2,894 shares.

On July 8, 2026, Agios Pharmaceuticals, Inc. insider Jay T. Backstrom reported the settlement of 1,447 restricted stock units (RSUs) into an equal number of shares of common stock, with no exercise price indicated, reflecting routine vesting of prior equity awards. The Form 4 shows an acquisition of 1,447 shares of common stock associated with the RSU vesting and a corresponding RSU disposition coded as “M” (conversion of derivative security), resulting in direct ownership of 2,894 shares of common stock following the transaction. The RSUs were originally granted on July 8, 2025 and are scheduled to vest in three equal annual installments beginning July 8, 2026, consistent with standard executive compensation practices rather than an open‑market purchase or discretionary sale.

Filing Facts

CIK

1439222

Ticker

AGIO

Form

4

Source Type

fda

Accession

0001439222-26-000112

Alert Tier

4